LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

LLY

1,047.61

+3.85%↑

JNJ

245.95

+1.42%↑

ABBV

228.48

+1.66%↑

NVS

164.11

+0.87%↑

MRK

123.18

+0.75%↑

Home・Aandelen Lijst・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Open

SectorGezondheidszorg

11.65 2.46

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.17

Max

11.84

Belangrijke statistieken
By Trading Economics
Inkomsten	11M -20M
Verkoop	5.9M 40M
Winstmarge	-49.569
Werknemers	184
EBITDA	16M -19M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+89.22% upside

Dividenden
By Dow Jones
Volgende Winsten	24 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	417M 1.2B
Vorige openingsprijs	9.19
Vorige sluitingsprijs	11.65

Nieuwssentiment

By Acuity

50%

141 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

6.26 / 7.47 Steun & Weerstand

Day One Biopharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 feb 2026, 23:55 UTC

Marktinformatie

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 feb 2026, 23:53 UTC

Marktinformatie

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 feb 2026, 23:53 UTC

Marktinformatie

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 feb 2026, 23:51 UTC

Marktinformatie

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 feb 2026, 23:35 UTC

Marktinformatie

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 feb 2026, 23:21 UTC

Winsten

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 feb 2026, 23:20 UTC

Winsten

Nickel Industries 2025 Operating Profit US$126.4 Million

22 feb 2026, 23:19 UTC

Winsten

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 feb 2026, 23:19 UTC

Winsten

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 feb 2026, 23:18 UTC

Winsten

Nickel Industries Won't Pay a Final Dividend

22 feb 2026, 23:16 UTC

Winsten

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 feb 2026, 21:35 UTC

Winsten

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 feb 2026, 21:34 UTC

Winsten

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 feb 2026, 21:34 UTC

Winsten

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 feb 2026, 21:33 UTC

Winsten

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 feb 2026, 21:33 UTC

Winsten

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 feb 2026, 21:28 UTC

Winsten

Ampol Final Dividend A$0.60/Share

22 feb 2026, 21:28 UTC

Winsten

Ampol FY Revenue A$31.37 Billion, Down 10%

22 feb 2026, 21:28 UTC

Winsten

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 feb 2026, 21:28 UTC

Winsten

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 feb 2026, 14:31 UTC

Acquisities, Fusies, Overnames

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 feb 2026, 05:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

20 feb 2026, 23:12 UTC

Acquisities, Fusies, Overnames

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb 2026, 22:12 UTC

Winsten

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

20 feb 2026, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

20 feb 2026, 21:23 UTC

Winsten

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb 2026, 21:20 UTC

Marktinformatie

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb 2026, 21:01 UTC

Acquisities, Fusies, Overnames

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb 2026, 20:38 UTC

Marktinformatie

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Peer Vergelijking

Prijswijziging

Day One Biopharmaceuticals Inc Prognose

Koersdoel

By TipRanks

89.22% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22.29 USD 89.22%

Hoogste 29 USD

Laagste 16 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Day One Biopharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Day One Biopharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

6.26 / 7.47Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

141 / 351 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.